|
1
|
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
|
J Clin Oncol
|
2009
|
2.68
|
|
2
|
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
|
Blood
|
2011
|
2.44
|
|
3
|
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
|
Blood
|
2012
|
1.88
|
|
4
|
BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells.
|
Blood
|
2008
|
1.78
|
|
5
|
Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.
|
Leuk Lymphoma
|
2012
|
1.42
|
|
6
|
Clinical implications of the molecular genetics of chronic lymphocytic leukemia.
|
Haematologica
|
2013
|
1.17
|
|
7
|
Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
|
Genes Chromosomes Cancer
|
2011
|
1.17
|
|
8
|
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.
|
Blood
|
2014
|
1.09
|
|
9
|
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
|
Haematologica
|
2011
|
1.08
|
|
10
|
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group.
|
Br J Haematol
|
2002
|
1.06
|
|
11
|
T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.
|
Cancer
|
2006
|
1.01
|
|
12
|
Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
|
Cancer
|
2005
|
1.00
|
|
13
|
The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53.
|
Haematologica
|
2005
|
0.98
|
|
14
|
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
|
Br J Haematol
|
2012
|
0.95
|
|
15
|
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
|
Leuk Lymphoma
|
2008
|
0.93
|
|
16
|
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.
|
Genes Chromosomes Cancer
|
2011
|
0.93
|
|
17
|
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
|
Exp Hematol
|
2011
|
0.86
|
|
18
|
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
|
Am J Hematol
|
2014
|
0.86
|
|
19
|
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
|
Br J Haematol
|
2014
|
0.85
|
|
20
|
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
|
Cancer
|
2007
|
0.84
|
|
21
|
Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.
|
Genes Chromosomes Cancer
|
2015
|
0.83
|
|
22
|
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.
|
Br J Haematol
|
2011
|
0.80
|
|
23
|
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
|
Am J Hematol
|
2014
|
0.80
|
|
24
|
Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors.
|
Leuk Res
|
2009
|
0.80
|
|
25
|
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease.
|
Haematologica
|
2012
|
0.80
|
|
26
|
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network.
|
Leuk Lymphoma
|
2015
|
0.79
|
|
27
|
Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients.
|
Blood
|
2009
|
0.79
|
|
28
|
Enteral nutrition may cause false-positive results of Aspergillus galactomannan assay in absence of gastrointestinal diseases.
|
Mycoses
|
2011
|
0.79
|
|
29
|
IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells.
|
Leuk Res
|
2013
|
0.78
|
|
30
|
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance.
|
Hematol Oncol
|
2013
|
0.77
|
|
31
|
Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
|
Am J Clin Pathol
|
2011
|
0.76
|
|
32
|
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
33
|
Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia.
|
Br J Haematol
|
2014
|
0.75
|
|
34
|
Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period.
|
Br J Haematol
|
2005
|
0.75
|
|
35
|
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
|
Haematologica
|
2005
|
0.75
|